Effects of Dalfampridine on Cognition in Multiple Sclerosis

NCT02006160 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: dalfampridine
DRUG: placebo

Sponsor

State University of New York at Buffalo